MiR-519d Suppresses Breast Cancer Tumorigenesis and Metastasis Via Targeting MMP3

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2018 Feb 28

PMID 29483840

Citations 30

Authors

Chengling Chu

Xin Liu

Xue Bai

Tong Zhao

Mengxue Wang

Ranchen Xu

Mingqi Li

Yingying Hu

Weihua Li

Lida Yang

Youyou Qin

Meng Yang

Chaoqi Yan

Yong Zhang

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is the most common cause of death in women throughout the world. Although microRNAs (miRNAs) have been identified as novel regulators in carcinogenesis, there are still abundant hidden treasure needed to be excavated. In the present study, we found that miR-519d expression was remarkably decreased in both human BC tissues and MCF-7 cells. CCK8 and 5-Ethynyl-2'-deoxyuridine (EdU) assays were used to evaluate cell proliferation. Wound-healing and transwell assays were performed for detection of cell migration and invasion. The results demonstrated miR-519d overexpression dramatically suppressed MCF-7 cells proliferation, migration and invasion. While downregulation of miR-519d by miR-519d inhibitor substantially increased MCF-7 cell carcinogenesis. Further analysis identified Matrix Metalloproteinase-3 (MMP3) as a direct target of miR-519d. QRT-PCR and western blot results indicated the correlative expression of miR-519d and MMP3 in BC tissues and MCF-7 cells. In summary, our data uncovered the novel molecular interaction between miR-519d and MMP3, indicating a therapeutic strategy of miR-519d for BC.

Citing Articles

Single-cell and spatial transcriptomics reveal pre-metastatic subsets and therapeutic targets in penile carcinoma.

Xu D, Chen L, Han H, Mo M iScience. 2025; 28(2):111765.

PMID: 39925432 PMC: 11804784. DOI: 10.1016/j.isci.2025.111765.

Endothelial-to-mesenchymal transition in the tumor microenvironment: Roles of transforming growth factor-β and matrix metalloproteins.

Du F, Li J, Zhong X, Zhang Z, Zhao Y Heliyon. 2024; 10(21):e40118.

PMID: 39568849 PMC: 11577214. DOI: 10.1016/j.heliyon.2024.e40118.

The Role and Function of Secretory Protein Matrix Metalloproteinase-3 () in Cervical Cancer.

Shao L, Liu W, Zhang C, Ma W, Yu X, Han J Iran J Public Health. 2024; 53(4):855-866.

PMID: 39444485 PMC: 11493579. DOI: 10.18502/ijph.v53i4.15562.

YWHAB is regulated by IRX5 and inhibits the migration and invasion of breast cancer cells.

Geng X, Yuan J, Xu W, Zou D, Sun Y, Li J Oncol Lett. 2024; 28(4):469.

PMID: 39119237 PMC: 11306988. DOI: 10.3892/ol.2024.14602.

A novel signature constructed by mitochondrial function and cell death-related gene for the prediction of prognosis in bladder cancer.

Yan Z, Liu Y, Wang M, Wang L, Chen Z, Liu X Sci Rep. 2024; 14(1):14667.

PMID: 38918587 PMC: 11199696. DOI: 10.1038/s41598-024-65594-0.

References

Boo L, Ho W, Ali N, Yeap S, Ky H, Chan K . MiRNA Transcriptome Profiling of Spheroid-Enriched Cells with Cancer Stem Cell Properties in Human Breast MCF-7 Cell Line. Int J Biol Sci. 2016; 12(4):427-45. PMC: 4807162. DOI: 10.7150/ijbs.12777. View

Yue H, Tang B, Zhao Y, Niu Y, Yin P, Yang W . MIR-519d suppresses the gastric cancer epithelial-mesenchymal transition via Twist1 and inhibits Wnt/β-catenin signaling pathway. Am J Transl Res. 2017; 9(8):3654-3664. PMC: 5575179. View

Zhang T, Hu Y, Ju J, Hou L, Li Z, Xiao D . Downregulation of miR-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN/MADD domain containing 2D. Sci Rep. 2016; 6:19346. PMC: 4726064. DOI: 10.1038/srep19346. View

Sternlicht M, Lochter A, Sympson C, Huey B, Rougier J, Gray J . The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999; 98(2):137-46. PMC: 2853255. DOI: 10.1016/s0092-8674(00)81009-0. View

Nassar F, Nasr R, Talhouk R . MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2016; 172:34-49. DOI: 10.1016/j.pharmthera.2016.11.012. View

Roy R, Yang J, Moses M . Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009; 27(31):5287-97. PMC: 2773480. DOI: 10.1200/JCO.2009.23.5556. View

Correia A, Mori H, Chen E, Schmitt F, Bissell M . The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with HSP90β. Genes Dev. 2013; 27(7):805-17. PMC: 3639420. DOI: 10.1101/gad.211383.112. View

Deryugina E, Quigley J . Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25(1):9-34. DOI: 10.1007/s10555-006-7886-9. View

Wang Z, Tan Y, Yu W, Zheng S, Zhang S, Sun L . Small role with big impact: miRNAs as communicators in the cross-talk between cancer-associated fibroblasts and cancer cells. Int J Biol Sci. 2017; 13(3):339-348. PMC: 5370441. DOI: 10.7150/ijbs.17680. View

10.

Gilam A, Conde J, Weissglas-Volkov D, Oliva N, Friedman E, Artzi N . Local microRNA delivery targets Palladin and prevents metastatic breast cancer. Nat Commun. 2016; 7:12868. PMC: 5031803. DOI: 10.1038/ncomms12868. View

11.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

12.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

13.

Shoshan E, Braeuer R, Kamiya T, Mobley A, Huang L, Vasquez M . NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis. Cancer Res. 2016; 76(11):3145-55. PMC: 4891299. DOI: 10.1158/0008-5472.CAN-15-2511. View

14.

Li Y, Sarkar F . MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer. Int J Biol Sci. 2016; 12(3):326-37. PMC: 4753161. DOI: 10.7150/ijbs.15017. View

15.

Dowdy S . Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017; 35(3):222-229. DOI: 10.1038/nbt.3802. View

16.

Xu T, Xiao D . Oleuropein enhances radiation sensitivity of nasopharyngeal carcinoma by downregulating PDRG1 through HIF1α-repressed microRNA-519d. J Exp Clin Cancer Res. 2017; 36(1):3. PMC: 5216549. DOI: 10.1186/s13046-016-0480-2. View

17.

Tartari F, Santoni M, Pistelli M, Berardi R . Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035). Cancer Treat Rev. 2017; 60:12-17. DOI: 10.1016/j.ctrv.2017.08.005. View

18.

Aroner S, Rosner B, Tamimi R, Tworoger S, Baur N, Joos T . Plasma matrix metalloproteinase 1, 3, and 7 levels and breast cancer risk in the Nurses' Health study. Cancer Causes Control. 2014; 25(12):1717-23. PMC: 4237657. DOI: 10.1007/s10552-014-0462-7. View

19.

Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

20.

Zhou J, Zheng S, Liu J, Shi R, Yu H, Wei M . MiR-519d facilitates the progression and metastasis of cervical cancer through direct targeting Smad7. Cancer Cell Int. 2016; 16:21. PMC: 4802873. DOI: 10.1186/s12935-016-0298-1. View